Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

Launched by LIFE MOLECULAR IMAGING GMBH · Jan 7, 2022

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a special imaging technique called PET (Positron Emission Tomography) using a substance called [18F]Florbetaben. The goal is to see if this imaging can help diagnose a condition known as cardiac amyloidosis, which affects the heart. This study is currently looking for patients aged 18 and older who might have this condition or related issues, such as having heart failure or abnormal heart measurements. Participants will need to provide consent and could be undergoing other tests to confirm their diagnosis.

If you join this trial, you will receive a single dose of the imaging agent and then undergo a PET scan, which will take about an hour. It's important to note that certain people cannot participate, such as those with severe liver problems or allergies to the study drug. Also, women who are pregnant or breastfeeding are not eligible. Overall, this study aims to improve how we diagnose heart-related issues linked to amyloidosis, potentially leading to better treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Males and females age ≥18 years
• • Able to understand, sign and date written informed consent
• • Written informed consent must be obtained before any study procedures are performed
• • Subjects being considered for a possible diagnosis of cardiac amyloidosis by
• * 1. One of the following conditions:
• • Established systemic amyloidosis without proven cardiac involvement,
• • Known plasma cell dyscrasia (MGUS, multiple myeloma),
• • Pathological free light chain levels in urine or serum,
• • Presence of heart failure with preserved ejection fraction
• * 2. AND one of the following parameters, indicative of cardiac manifestation:
• • Mean (left ventricular (LV) wall + septum) thickness \>12mm as measured by echocardiography or CMR in absence of other known cause of left ventricular hypertrophy (LVH),
• • NT-proBNP \>335 ng/L (in case a value for NT-proBNP is not available, BNP \> 81ng/L may be used instead)
• • Planned diagnostic procedure to establish diagnosis and cardiac involvement (e.g., endomyocardial biopsy or extracardiac biopsy in conjunction with cardiac magnetic resonance imaging/echocardiography or bone scintigraphy)
• • Female subjects must be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause). If they are of child-bearing potential, they must commit to use of a highly effective contraceptive measure for at least one week following the PET scan (including combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilaterial tubal occlusion, vasectomised parner or secual abstinence).
• • Male subjects and their partners of childbearing potential must commit to the use of a highly effective method of contraception for a minimum of 90 days following the PET scan (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), intrauterine device, intrauterine hormone-releasing system, bilaterial tubal occlusion, male subjects with vasectomy or sexual abstinence)
• • Male subjects must commit to not donate sperm for a minimum of 90 days after the PET scan
• Exclusion Criteria:
• • Any known allergic reactions or hypersensitivity towards any compound of the study drug
• • Severe hepatic impairment (AST/ALT \>5 x ULN; bilirubin \>3 x ULN)
• • Inability to lay flat for up to 60 min
• • Pregnant, lactating or breastfeeding
• • Unwilling and/or unable to cooperate with study procedures
• • Having been administered a radiopharmaceutical within 10 radioactive half-lives prior to study drug administration in this study